Related Experiment Video
Updated: Jul 14, 2026

Practical Use of RNA Interference: Oral Delivery of Double-stranded RNA in Liposome Carriers for Cockroaches
Published on: May 1, 2018
Targeted delivery systems of small interfering RNA by systemic administration
Shigeru Kawakami1, Mitsuru Hashida
1Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. kawakami@pharm.kyoto-u.ac.jp
Small interfering RNA (siRNA) holds therapeutic promise, but in vivo delivery faces challenges like degradation and immune responses. This review explores recent advancements in siRNA delivery systems and understanding immune reactions for effective in vivo therapy.
Area of Science:
- Molecular Biology
- Biotechnology
- Pharmacology
Background:
- RNA interference (RNAi) utilizes small interfering RNA (siRNA) to silence target messenger RNA (mRNA).
- In vivo delivery of siRNA is hindered by enzymatic degradation, blood component interactions, and cellular uptake issues affecting biodistribution.
- Therapeutic applications of siRNA require careful consideration of potential immune responses.
Purpose of the Study:
- To review recent developments in siRNA delivery systems for in vivo applications.
- To discuss the immunological aspects associated with siRNA administration.
- To provide an overview of strategies overcoming in vivo delivery obstacles.
Main Methods:
- Literature review of recent scientific reports and publications.
- Analysis of physical and pharmaceutical approaches for siRNA delivery.
- Examination of studies investigating siRNA-induced immune responses.
Main Results:
- Various delivery systems, including physical and pharmaceutical methods, have been proposed to enhance in vivo siRNA efficacy.
- Understanding and mitigating siRNA-induced immune responses are critical for successful therapeutic outcomes.
- Biodistribution and cellular uptake remain key challenges in siRNA delivery.
Conclusions:
- Advancements in delivery systems are crucial for overcoming in vivo siRNA obstacles.
- Addressing immune responses is essential for the clinical translation of siRNA therapeutics.
- Further research is needed to optimize siRNA delivery and safety for therapeutic use.
More Related Videos
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
09:36Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
Related Concept Videos
Experimental RNAi
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Modified-Release Drug Delivery Systems: Site-Targeted
Small interfering RNAs (siRNA)
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...